Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Reexamination Certificate
2006-10-10
2006-10-10
Nazario-Gonzalez, Porfirio (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
C514S492000, C424S650000
Reexamination Certificate
active
07119217
ABSTRACT:
Provided are novel tri(alkylcarboxylato) gallium (III) compounds, exemplified by tripalmitato gallium (III), methods for making them, pharmaceutical compositions containing them, and methods of using the pharmaceutical compositions.
REFERENCES:
patent: 4529593 (1985-07-01), Warrell, Jr. et al.
patent: 5175006 (1992-12-01), Matkovic et al.
patent: 5177068 (1993-01-01), Callingham et al.
patent: 5258376 (1993-11-01), Bernstein
patent: 5281578 (1994-01-01), Bradley et al.
patent: 5574027 (1996-11-01), Bernstein
patent: 5747482 (1998-05-01), Bernstein
patent: 5883088 (1999-03-01), Bernstein
patent: 5968922 (1999-10-01), Bernstein
patent: 5981518 (1999-11-01), Bernstein
patent: 5998397 (1999-12-01), Bernstein
patent: 6004951 (1999-12-01), Bernstein
patent: 6048851 (2000-04-01), Bernstein
patent: 6087354 (2000-07-01), Bernstein
patent: 6656615 (2003-12-01), Dwilinski et al.
patent: 2005/0220895 (2005-10-01), Bucalo et al.
patent: 0 502 709 (1992-09-01), None
Hart et al., “Antitumor Activity and Toxicity of Salts of Inorganic Group IIIa Metals: Aluminum, Gallium, Indium, and Thallium,” Proc. Natl. Acad. Sci USA, vol. 68, No. 7 (Jul. 1971) pp. 1623-1626.
D.J. Straus, “Gallium Nitrate in the Treatment of Lymphoma,” Seminars in Oncology, vol. 30, No. 2, Suppl. 5 (Apr. 2003) pp. 25-33.
E.A. Van Leeuwen-Stok et al., “Cell Cycle Dependency of67Gallium Uptake and Cytotoxicity in Human Cell Lines of Hematological Malignancies,” Leukemia and Lymphoma, vol. 31(5-6) (Nov. 1998) pp. 533-544.
R.P. Warrell, Jr. et al., “Salvage Chemotherapy of Advanced Lymphoma with Investigational Drugs: Mitoguazone, Gallium Nitrate, and Etoposide1,2,” Cancer Treatment Response, vol. 71, No. 1 (Jan. 1987) pp. 47-51.
M.S. Myette et al., “Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells,” Cancer Letters, vol. 129, No. 2 (Jul. 17, 1998) pp. 199-204.
C.R. Chitambar et al., “Evaluation of Continuous-Infusion Gallium Nitrate and Hydroxyurea in Combination for the Treatment of Refractory Non-Hodgkin's Lymphoma,” Am. J. Clin. Oncol., vol. 20, No. 2 (Apr. 1997) pp. 173-178.
R.P. Warrell et al., “Gallium Nitrate Inhibits Calcium Resorption from Bone and is Effective Treatment for Cancer-related Hypercalcemia,” J. Clin. Invest., vol. 73 (May 1984) pp. 1487-1490.
R.P. Warrell, Jr. et al., “Gallium Nitrate for Preservation of Bone Mass in Multiple Myeloma: Results of a Pilot Randomized Study,” Journal of Bone and Mineral Research, vol. 5 (Suppl. 2) (Aug. 28, 1990) pp. S106.
R.P. Warrell, Jr. et al., “Low-Dose Gallium Nitrate for Prevention of Osteolysis in Myeloma: Results of a Pilot Randomized Study,” Journal of Clinical Oncology, vol. 11, No. 12 (Dec. 1993) pp. 2443-2450.
R.P. Warrell, Jr., “Gallium Nitrate for the Treatment of Bone Metastases,” Cancer, vol. 80, No. 8 (Oct. 15, 1997) pp. 1680-1685.
C.R. Chitambar, “Gallium Nitrate Revisited,” Seminars in Oncology, vol. 30, No. 2, Suppl. 5 (Apr. 2003) pp. 1-4.
R.P. Warrell, Jr. et al., “Gallium Nitrate for Advanced Paget Disease of Bone: Effectiveness and Dose-REsponse Analysis,” Annals of Internal Medicine, vol. 113, No. 11 (Dec. 1990) pp. 847-851.
R. Bockman, “The Effects of Gallium Nitrate on Bone Resorption,” Seminars in Oncology, vol. 30, No. 2, Suppl.5 (Apr. 2003) pp. 5-12.
N. Makkonen et al., “The effect of free gallium and gallium in liposomes on cytokine and nitric oxide secretion from macrophage-like cells in vitro,” Inflamm. Res., vol. 44, No. 12 (Dec. 1995) pp. 523-528.
G. Apseloff, “Therapeutic Uses of Gallium Nitrate: Past, Present, and Future,” American Journal of Therapeutics, No. 6 (1999) pp. 327-339.
I.M. Viktorova et al., “Gallium and Indium Acylates,” pp. 929-930; translated from Doklady Akademii Nauk SSSR, vol. 189, No. 3 (Nov. 1969) pp. 541-542.
H.C. Dudley et al., “Preparation and Properties of Gallium Lactate1,” The Journal of the American Chemical Society, vol. 70 (Sep.-Dec. 1948) p. 3942-3943.
Per Artursson et al., “Caco-2-Monolayers in Experimental and Theoretical Predictions of Drug Transport,” Advanced Drug Delivery Reviews, vol. 46 (2001) pp. 27-43.
Shiyin Yee, “In Vitro Permeability Acros Caco-2-Cells (Colonic) Can Predict in Vivo (Small Intestinal) Absorption in Man—Fact or Myth,” Pharmaceutical Research, vol. 14, No. 6 (1997) pp. 763-766.
Edward Rudnic et al., “Oral Solid Dosage Forms,” Chapter 92,Remington: The Science and Practice of Pharmacy, vol. II, Alfonso R. Gennaro, Ed., 1995, pp. 1615-1649.
Jiang Jack B.
Klem Robert E.
Ramaswamy Kollengode K.
Warrell, Jr. Raymond P.
Genta Incorporated
Nazario-Gonzalez Porfirio
LandOfFree
Tri(alkylcarboxylato)gallium (III) products and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tri(alkylcarboxylato)gallium (III) products and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tri(alkylcarboxylato)gallium (III) products and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3646405